ARWR - Arrowhead Pharmaceuticals - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

ARWR is currently covered by 12 analysts with an average price target of $36.66. This is a potential upside of $20.35 (124.77%) from yesterday's end of day stock price of $16.31.

Arrowhead Pharmaceuticals's activity chart (see below) currently has 194 price targets and 179 ratings on display. The stock rating distribution of ARWR is 84.78% BUY and 15.22% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 66.83% with an average time for these price targets to be met of 256.95 days.

Highest price target for ARWR is $80, Lowest price target is $26, average price target is $44.5.

Most recent stock forecast was given by PATRICK TRUCCHIO from HC WAINWRIGHT on 20-May-2025. First documented stock forecast 18-Dec-2013.

Currently out of the existing stock ratings of ARWR, 39 are a BUY (84.78%), 7 are a HOLD (15.22%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$80

$64.2 (406.33%)

$80

2 months 17 days ago
(20-May-2025)

0/22 (0%)

$63.71 (391.10%)

Buy

$60

$44.2 (279.75%)

$60

2 months 24 days ago
(13-May-2025)

4/20 (20%)

$44.72 (292.67%)

193

Buy

$38

$22.2 (140.51%)

$55

5 months 23 days ago
(14-Feb-2025)

8/16 (50%)

$18.89 (98.85%)

135

Buy

$42

$26.2 (165.82%)

$42

5 months 26 days ago
(11-Feb-2025)

2/10 (20%)

$23.11 (122.34%)

100

Buy

$45

$29.2 (184.81%)

$62

8 months 10 days ago
(27-Nov-2024)

22/36 (61.11%)

$18.85 (72.08%)

154

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is ARWR (Arrowhead Pharmaceuticals) average time for price targets to be met?

On average it took 256.95 days on average for the stock forecasts to be realized with a an average price target met ratio 66.83

Which analyst has the current highest performing score on ARWR (Arrowhead Pharmaceuticals) with a proven track record?

LUCA ISSI

Which analyst has the most public recommendations on ARWR (Arrowhead Pharmaceuticals)?

Luca Issi works at RBC and has 10 price targets and 7 ratings on ARWR

Which analyst is the currently most bullish on ARWR (Arrowhead Pharmaceuticals)?

Esther Rajavelu with highest potential upside - $75.13

Which analyst is the currently most reserved on ARWR (Arrowhead Pharmaceuticals)?

Alethia Young with lowest potential downside - -$0

Arrowhead Pharmaceuticals in the News

Arrowhead unit sells rights for plozasiran to Sanofi in Greater China

[Gratitude Concept With Heart Symbol] Eoneren/E+ via Getty Images Arrowhead Pharmaceuticals (NASDAQ:ARWR [https://seekingalpha.com/symbol/ARWR]) said it has signed an asset purchase agreement between Sanofi and a subsidiary of the company, Visirna Therapeutics, which focuses on developing cardiometabolic treatments in Greater China. Under the agreement, Sanofi will obtain an exclusive license to further develop and commercialize plozasiran...

Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi

– Sanofi to pay $130 million upfront and up to $265 million in potential regulatory milestones to Visirna Therapeutics, a majority-owned subsidiary of Arrowhead, which was previously granted rights to investigational plozasiran in Greater China – Sanofi will receive an exclusive license to develop and commercialize investigational plozasiran in Greater China from Visirna Therapeutics, offering...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?